A major focus of our group is to find new targets on cancer cells that can be used in CAR therapy. We have identified BAFF-R, a surface receptor that is overexpressed in mantle-cell lymphoma and on B-cells, and developed new CARs that utilize this antigen. This work has given new insights into the biology of BAFF-R, and how CARs with varying affinity affect T-cell efficacy and the development of cancer escape variants.
A new target against lymphoma
